z-logo
open-access-imgOpen Access
Cytotoxic activity of green synthesis copper oxide nanoparticles using cordia myxa L. aqueous extract on some breast cancer cell lines.
Author(s) -
Neran Ali Thamer,
Nadia Tareq Barakat
Publication year - 2019
Publication title -
journal of physics. conference series
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 85
eISSN - 1742-6596
pISSN - 1742-6588
DOI - 10.1088/1742-6596/1294/6/062104
Subject(s) - copper , aqueous solution , nanoparticle , chemistry , nuclear chemistry , growth inhibition , cytotoxicity , cytotoxic t cell , cell culture , silver nanoparticle , mcf 7 , cancer cell , cell growth , human breast , cancer , nanotechnology , biochemistry , organic chemistry , in vitro , materials science , medicine , biology , genetics
The efficiency of copper oxide nanoparticles synthesized from aqueous extract of cordia myxa L. on some breast cancer lines AMJ-13,MCF-7, and HBL-100 as normal cell lines was studied. Different concentration of copper oxide nanoparticles (25,50,75,100) µg/ml at different times (24,48 and72) h were selected. The results showed that the effect of nanoparticles depend on the concentration. As the concentration of nanoparticles increase the percent of inhibition increase. It was found that concentration of copper oxide nanoparticles at 100 μg / ml gave the highest inhibitory rate of cell growth MCF-7 (71.1%) after 24 hours, while the percent of inhibition for AMJ-13 was (69.6)%. When the exposure time was increased to48 h, the rate of inhibition at 100 mg/ml was 80% for MCF-7 while 73% for AMJ13. By increasing the duration of the exposure to 72 hours, the rate of inhibition at l00µg/ml were (85.2 and 78.2)for MCF-7 and AMJ13 respectively. No significant inhibition was found for HBL-100 at different concentration and different times. These results was indicated that copper oxide nanoparticles synthesized from the aqueous extract of cordia myxa L. had a toxic effect on growth of some breast cancer cell lines.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here